The development of depot contraceptives
Shearman, R.P.
Journal of Steroid Biochemistry 6(6): 899-902
1975
ISSN/ISBN: 0022-4731 PMID: 1177432 DOI: 10.1016/0022-4731(75)90323-4Document Number: 505369
Document emailed within 0-6 h
Related Documents
Torok, M.R.; Miller, W.C.; Hobbs, M.M.; Macdonald, P.D.M.; Leone, P.A.; Schwebke, J.R.; Seña, A.C. 2009: The association between oral contraceptives, depot-medroxyprogesterone acetate, and trichomoniasis Sexually Transmitted Diseases 36(6): 336-340Fathizadeh, N.; Abdi, F.; Savabi, M. 2011: A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD Iranian Journal of Nursing and Midwifery Research 16(4): 304-308
Nanda, K.; Morrison, C.S.; Kwok, C.; Byamugisha, J.; Jones, L.; Sriplienchan, S.; Magwali, T. 2011: Discontinuation of oral contraceptives and depot medroxyprogesterone acetate among women with and without HIV in Uganda, Zimbabwe and Thailand Contraception 83(6): 542-548
Clark, M.K.; Stockdale, C.K.; Railsback, L.; Nichols, S. 2011: Differences in cervical cytologic and histologic findings between women using depot-medroxyprogesterone acetate and oral contraceptives Journal of Lower Genital Tract Disease 15(3): 219-223
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
Thomas, D.B.; Ye, Z.; Ray, R.M. 1995: Cervical carcinoma in situ and use of depot-medroxyprogesterone acetate (DMPA). WHO Collaborative Study of Neoplasia and Steroid Contraceptives Contraception 51(1): 25-31
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 191-195
von Schrader, H.W.; Buscher, G.; Dierdorf, D.; Freytag, A.; Mügge, H.; Wolf, D. 1985: Bioavailability and tolerance of xanthinol nicotinate depot preparations. Comparison of a conventional 500 mg xanthinol nicotinate depot tablet with new 500 mg and 1 g depot tablets Arzneimittel-Forschung 35(9): 1468-1472
Thomas, D.B.; Ray, R.M. 1995: Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives Contraception 52(5): 307-312
Who 1982: Multinational comparative clinical trial of long acting injectable contraceptives norethisterone enanthate given in 2 dosage regimens and depot medroxy progesterone acetate Contraception 25(1): 1-12
Who 1982: Multinational comparative clinical trial of long acting injectable contraceptives norethisterone enanthate given in 2 dosage regimens and depot medroxy progesterone acetate Contraception 25(1): 1-12
Wanichsetakul, P.; Kamudhamas, A.; Watanaruangkovit, P.; Siripakarn, Y.; Visutakul, P. 2002: Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception Contraception 65(6): 407-410
Sippell, W.G.; Partsch, C.J.; Hümmelink, R.; Lorenzen, F. 1994: Long-term therapy of true precocious puberty in girls using Decapetyl-Depot, a superactive gonadoliberin agonist in depot microcapsulated form Ceskoslovenska Pediatrie 49(1): 13-18
Sas, M.; Gellen, J.J.; Dusitsin, N.; Tunkeyoon, M.; Chalapati, S.; Crawford, M.A.; Drury, P.J.; Lenihan, T.; Ayeni, O.; Pinol, A. 1986: An investigation on the influence of steroidal contraceptives on milk lipid and fatty acids in Hungary and Thailand. WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on oral contraceptives Contraception 33(2): 159-178
Sas, M.; Gellen, J.J.; Dusitsin, N.; Tunkeyoon, M.; Chalapati, S.; Crawford, M.A.; Drury, P.J.; Lenihan, T.; Ayeni, O.; Pinol, A. 1986: An investigation on the influence of steroidal contraceptives on milk lipid and fatty acids in Hungary and Thailand. WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on oral contraceptives Contraception 33(2): 159-178
Beksinska, M.E.; Kleinschmidt, I.; Smit, J.A.; Farley, T.M.M. 2009: Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate Contraception 79(5): 345-349
Tharnprisarn, W.; Taneepanichskul, S. 2002: Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: A cross-sectional study in young Thai women Contraception 66(2): 101-103
1989: The WHO multicentre trial of the vasopressor effects of combined oral contraceptives: 2. Lack of effect of estrogen. Task Force on Oral Contraceptives. WHO Special Programme of Research, Development and Research Training in Human Reproduction Contraception 40(2): 147-156